Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation

Proteasome inhibitor therapy for antibody-mediated rejection

(2015) E. S. Woodle et al.   PEDIATRIC TRANSPLANTATION

Pathologic basis of antibody-mediated organ transplant rejection

(2013) Amani Joudeh et al.   Current Opinion in Organ Transplantation

The proteasome and the degradation of oxidized proteins: Part I—structure of proteasomes

(2013) Tobias Jung et al.   Redox Biology

Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice

(2012) Y. Nagayama et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection

(2012) Tahmeena Ahmed et al.   JOURNAL OF CLINICAL APHERESIS

Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation

(2012) K. W. Kalim et al.   JOURNAL OF IMMUNOLOGY

The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in the NZB/W F1 Mouse Model by Preservation of Glomerular and Tubulointerstitial Architecture

(2012) Nadine Hainz et al.   NEPHRON EXPERIMENTAL NEPHROLOGY

Prospective Evaluation of the Toxicity Profile of Proteasome Inhibitor–Based Therapy in Renal Transplant Candidates and Recipients

(2012) Nicole Schmidt et al.   TRANSPLANTATION

The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients—A Systematic Review

(2012) Darren M. Roberts et al.   TRANSPLANTATION

The Use of Bortezomib as a Rescue Treatment for Acute Antibody-Mediated Rejection: Report of Three Cases and Review of Literature

(2012) I. Tzvetanov et al.   TRANSPLANTATION PROCEEDINGS

In Vitro Effects of Rituximab on the Proliferation, Activation and Differentiation of Human B Cells

(2011) E. G. Kamburova et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Summary of FDA Antibody-Mediated Rejection Workshop

(2011) P. Archdeacon et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Desensitization Protocols and Their Outcome

(2011) K. Marfo et al.   Clinical Journal of the American Society of Nephrology

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

(2011) D. J. Kuhn et al.   CURRENT CANCER DRUG TARGETS

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

(2011) B. C. Potts et al.   CURRENT CANCER DRUG TARGETS

Emerging drugs for the treatment of transplant rejection

(2011) Lars P Kihm et al.   EXPERT OPINION ON EMERGING DRUGS

Clinical and investigational use of proteasome inhibitors for transplant rejection

(2011) Basma Sadaka et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antibody-mediated rejection in kidney transplantation: an update

(2011) Jessica G Lucas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis

(2011) A. M. Gomez et al.   JOURNAL OF IMMUNOLOGY

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection

(2011) J. Waiser et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition

(2011) R. Carlin Walsh et al.   TRANSPLANTATION

An Integrated View of Molecular Changes, Histopathology and Outcomes in Kidney Transplants

(2010) P. F. Halloran et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Bortezomib as the Sole Post-Renal Transplantation Desensitization Agent Does Not Decrease Donor-Specific Anti-HLA Antibodies

(2010) R. Sberro-Soussan et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome

(2010) M. Basler et al.   JOURNAL OF IMMUNOLOGY

Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection

(2010) Joanna Ashton-Chess et al.   KIDNEY INTERNATIONAL

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Protective Immunity Remains Intact After Antibody Removal by Means of Proteasome Inhibition

(2010) Matthew J. Everly et al.   TRANSPLANTATION

Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection

(2010) R Carlin Walsh et al.   TRANSPLANTATION

The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation

(2010) Stuart M. Flechner et al.   TRANSPLANTATION

Mechanisms of Alloantibody Production in Sensitized Renal Allograft Recipients

(2009) M. D. Stegall et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss

(2009) M. J. Everly et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Comparison of Combination Plasmapheresis/IVIg/Anti-CD20 Versus High-Dose IVIg in the Treatment of Antibody-Mediated Rejection

(2009) C. Lefaucheur et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies

(2009) A. Loupy et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Impact of rituximab therapy for treatment of acute humoral rejection

(2009) Z. Kaposztas et al.   CLINICAL TRANSPLANTATION

Proteasome inhibition for antibody-mediated rejection

(2009) Jason J Everly et al.   Current Opinion in Organ Transplantation

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

A Single Low-Fixed Dose of Rituximab to Salvage Renal Transplants From Refractory Antibody-Mediated Rejection

(2009) William R. Mulley et al.   TRANSPLANTATION

Abrogation of Anti-HLA Antibodies via Proteasome Inhibition

(2009) Hargovind L. Trivedi et al.   TRANSPLANTATION

HLA-Specific Antibodies Developed in the First Year Posttransplant are Predictive of Chronic Rejection and Renal Graft Loss

(2009) Po-Chang Lee et al.   TRANSPLANTATION

Proteasome Inhibition Reduces Donor-Specific Antibody Levels

(2009) M.J. Everly et al.   TRANSPLANTATION PROCEEDINGS

A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation

(2008) V. Zarkhin et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production

(2008) D. K. Perry et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

(2008) K. Solez et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Anti-Inflammatory Actions of Intravenous Immunoglobulin

(2008) Falk Nimmerjahn et al.   Annual Review of Immunology

Role of natural antibodies in immune homeostasis: IVIg perspective

(2008) Janakiraman Vani et al.   AUTOIMMUNITY REVIEWS

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE

Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

(2008) Matthew J. Everly et al.   TRANSPLANTATION

Antibody-mediated rejection: treatment alternatives and outcomes

(2008) Neeraj Singh et al.   Transplantation Reviews